{"id":3708,"date":"2015-10-20T00:00:00","date_gmt":"2015-10-19T15:00:00","guid":{"rendered":"https:\/\/inpsjapan.com\/en\/?p=3708"},"modified":"2023-07-02T00:08:19","modified_gmt":"2023-07-01T15:08:19","slug":"japans-development-agency-assisting-kenyas-fight-against-tb","status":"publish","type":"post","link":"https:\/\/inpsjapan.com\/en\/sdgs-2\/goal3\/japans-development-agency-assisting-kenyas-fight-against-tb\/","title":{"rendered":"Japan\u2019s Development Agency Assisting Kenya\u2019s Fight Against TB"},"content":{"rendered":"\n<p>NAIROBI (IDN) &#8211; Catherine Nduta, 26, was diagnosed with Multi Drug Resistant Tuberculosis (MDR-TB) in 2012, when she was a third year student at one of Kenya\u2019s universities, where she was undertaking a civil engineering course.<\/p>\n\n\n\n<p>\u201cI was almost 6-month pregnant hence couldn\u2019t start MDR-TB treatment. I was to either terminate the pregnancy for me to start medication or continue with normal TB medication until I give birth,\u201d Nduta told a forum organized by&nbsp;<a href=\"http:\/\/www.stoptb.org\/countries\/partnerships\/np_ken.asp\">StopTB Partnership Kenya<\/a>, that attracted Kenya\u2019s Members of Parliament (MPs).<\/p>\n\n\n\n<p>\u201cI finally underwent induction and my baby was removed prematurely for me to start medication. 12 months of injections and 24 months of taking 18 pills a day: life was hard,\u201d says she, now mother of one son.\u00a0|<a href=\"https:\/\/inpsjapan.com\/news\/japans-development-agency-assisting-kenyas-fight-against-tb\/\">\u00a0JAPANESE<\/a><\/p>\n\n\n\n<p>Nduta is not a lone sufferer of MDR-TB. Nairobi and Mombasa, Kenya\u2019s two biggest cities, host the highest number of normal tuberculosis cases due to poor urban settlements and high population.<\/p>\n\n\n\n<p>60 percent of Nairobi\u2019s 3.5 million population is living in slums because of an unavoidable deficit in housing, sanitation and nutrition, which make people vulnerable to infection.<\/p>\n\n\n\n<p>\u201cDrug Resistant TB (DR-TB) is an emerging threat in Kenya because of the difficulty in diagnosis and treatment. Its treatment takes close to 20 months and requires a direct cost of drugs of up to 3 million Kenyan Shillings (equivalent to some 28,000 USD),\u201d Dr. Enos Masini, head of tuberculosis, leprosy and lung disease at Kenya\u2019s Health Ministry, told IDN.<\/p>\n\n\n\n<p>\u201cMost of those who suffer from tuberculosis are poor and cannot afford pay for treatment,\u201d he added.<\/p>\n\n\n\n<p>With this in view, the Japan International Cooperation Agency (JICA) is engaged in supporting Kenya fight TB. Along with South Africa and Zambia, this East African nation ranks among three TB endemic countries in Africa.<\/p>\n\n\n\n<p>While public health officials were jittery in 2013 about rising cases of drug-resistant strains of TB, JICA donated high-tech TB testing equipment worth 32 million Kenyan Shillings (some 313,528.96 USD).<\/p>\n\n\n\n<p>\u201cStrengthening the capacity of laboratories and their network (application of new laboratory testing methods such as use of fluorescent microscopes, improving drugs susceptibility testing to identify drug DR-TB and improving quality assurance and testing) has been JICA\u2019s main area of assistance in TB control in recent years,\u201d Keiko Sano, Chief Representative of&nbsp;<a href=\"http:\/\/www.jica.go.jp\/kenya\/english\/\">JICA in Kenya<\/a>&nbsp;told IDN.<\/p>\n\n\n\n<p>JICA also donated 102 LED fluorescent microscopes to Kenya\u2019s Public Health Ministry. The country had only 20 of such machines in all the public health facilities.<\/p>\n\n\n\n<p>Kenya found itself in a dilemma in 2014 due to lack of MDR-TB drugs, and was constrained to borrow these from Malawi and neighbouring Uganda.<\/p>\n\n\n\n<p>\u201cIt was a big embarrassment,\u201d says Evlyn Kibuchi, chief national coordinator at StopTB Partnership Kenya, an organization that brings together partners in the fight against tuberculosis.<\/p>\n\n\n\n<p>Sano said the international community on the whole, not only JICA, is of the view that domestic financing is key to sustainable control of high-burden diseases such as TB.<\/p>\n\n\n\n<p><strong>Communicable disease control high on JICA\u2019s agenda<\/strong><\/p>\n\n\n\n<p>\u201cWe welcome the government of Kenya\u2019s commitment to gradually increase its domestic financing. Also integration of TB-related services with other health services can save costs. Maintaining quality of integrated services in this context is crucial,\u201d JICA\u2019s Chief Representative in Kenya told IDN in an interview.<\/p>\n\n\n\n<p>While Japan fully embraces the recently adopted 17 Sustainable Development Goals (SDGs) that will take over in December from the Millennium Development Goals (MDGs) for the next 15 years, Sano said, communicable disease control, TB included, is still high on JICA\u2019s agenda.<\/p>\n\n\n\n<p>\u201cJapan recently launched its new five-year global health policy (2016-2020). We are committed to assist Kenya to achieve Universal Health Coverage (UHC) and believe in strengthening health systems, which is the basis of diseases-specific programmes to perform better,\u201d Sano added.<\/p>\n\n\n\n<p>James Murgor, a Kenyan Member of Parliament and member of the national parliament health caucus committee, is concerned about donor fatigue in the wake of this East African nation being ranked as a middle-income country. He pleads for increased government funding to address TB.<\/p>\n\n\n\n<p>Murgor is referring to the&nbsp;<a href=\"http:\/\/www.worldbank.org\/en\/news\/press-release\/2015\/07\/01\/new-world-bank-update-shows-bangladesh-kenya-myanmar-and-tajikistan-as-middle-income-while-south-sudan-falls-back-to-low-income\">World Bank\u2019s latest estimates<\/a>&nbsp;of Gross National Income per capita (GNI), which continue to show improved economic performance in many low-income countries, with Bangladesh, Kenya, Myanmar, and Tajikistan now becoming lower-middle income countries, joining those with annual incomes of 1,046 dollars to 4,125 dollars.<\/p>\n\n\n\n<p>\u201cFor us here in Kenya, the fight against TB is 40 percent government-funded and 60 percent donor-funded, which is risky,\u201d Murgor explained the rationale behind his anxiety.<\/p>\n\n\n\n<p><a href=\"http:\/\/www.nltp.co.ke\/index.php?option=com_content&amp;view=article&amp;id=26&amp;Itemid=11\">According to the Health Ministry<\/a>, \u201cTuberculosis remains a major cause of morbidity and mortality in Kenya. It affects all age groups, but has its greatest toll in the most productive age group of 15 to 44 years.\u201d Estimates are that it claims 60 lives every day in Kenya.<\/p>\n\n\n\n<p>Furthermore, as KIbuchi says, \u201cTB is quite expensive when it comes to the workplace. It leads to absenteeism, workflow disruption, lose of productivity and direct cost to the affected person.\u201d<\/p>\n\n\n\n<p>It is estimated that world wide about 13 billion U.S. dollars are lost to TB, while Kenya loses about 110 million U.S. dollars.<\/p>\n\n\n\n<p>Takashi Miura, JICA\u2019s TB advisor, concurs with Kibuchi, arguing that the financial burden is considerable for MDR-TB patients since the treatment would take as long as two years.<\/p>\n\n\n\n<p>\u201cEven if the treatment itself is free-of-charge, the patients may not be able to work productively during the course of treatment therefore, loss of income would be inevitable,\u201d he told IDN.<\/p>\n\n\n\n<p>Only 1.3 percent of Kenya\u2019s total health expenditure goes toward TB, Kenya\u2019s fourth lead killer disease.<\/p>\n\n\n\n<p><strong>National&nbsp;<\/strong><strong>Strategic Plan on Tuberculosis<\/strong><\/p>\n\n\n\n<p>On March 19, 2015, Kenya launched its National Strategic Plan on Tuberculosis, Leprosy and Lung Diseases (NTLD Program) for the period 2015-2018. It involves an expenditure of 25 billion Kenyan Shillings (some 250 million USD).<\/p>\n\n\n\n<p>The government of Kenya has pledged some 5 billion Kenyan Shillings, the Global Fund about 7 billion while PEPFAR (the U.S. President&#8217;s Emergency Plan for AIDS Relief) has allocated under 7 billion, leaving an approximate budget gap of 6 billion Kenyan Shillings (some 59 million USD). In view of this, Dr. Masini of Kenya\u2019s Health ministry argues that lack of funds might derail targets.<\/p>\n\n\n\n<p>JICA\u2019s TB advisor Miura stresses the need to implement high quality directly observed treatment to avoid a situation that could lead to development of a drug-resistant TB.<\/p>\n\n\n\n<p>He further calls for establishment of patients\u2019 sample referrals system and introduction of new laboratory techniques in order to monitor and to detect DR-TB cases early among high risk groups such as previously treated TB patients, those who had contacts with DR-TB patients, refugees, prisoners and those who have TB symptoms.<\/p>\n\n\n\n<p>Launched early July 2015, Kenya\u2019s first ever tuberculosis survey since independence in 1963 seeks to determine the prevalence of tuberculosis in Kenya \u2013 with the last done in 1958-1959 when over 80 percent of Kenya\u2019s population was not born.<\/p>\n\n\n\n<p>\u201cWe are going to screen 72,000 Kenyans and we have already screened 12,000. The purpose is to find out how much of TB is there in community so as to make adequate plans to move towards elimination of tuberculosis,\u201d said Health Ministry\u2019s Dr Masini.<\/p>\n\n\n\n<p>JICA\u2019s TB control advisor Miura said findings from the on-going prevalence survey might not be easily comparable with the first survey (done in 1958-1959), for the survey methodology is not exactly the same and that there was no HIV infection then.<\/p>\n\n\n\n<p>\u201cThe ongoing survey will help in measuring the impact of TB control after the country\u2019s adoption of the directly observed treatment strategy. It will further locate where missing cases are at the moment,\u201d he said.<\/p>\n\n\n\n<p>\u201cIt will also help in having a better understanding of the health seeking behavior of those with symptomatic TB and also the results will inform new direction of TB control,\u201d said Miura.<\/p>\n\n\n\n<p>Kibuchi of StopTB Partnership Kenya told IDN that back in 2011 when JICA wanted to pull out its support towards the fight against TB, her organization wrote a memo requesting not to.<\/p>\n\n\n\n<p>\u201cWe did a memo requesting JICA not to pull out its support, and they agreed to continue for two more years. This is not the time for donor agencies to pull out as we seek to reduce TB prevalence,\u201d said Kibuchi.<\/p>\n\n\n\n<p>In 2014, Britain applauded Kenya for being the lead single country globally having 158 Members of Parliament signing commitment in support of the Barcelona Declaration, which established a new Global Parliamentary Caucus on TB to press for a more effective response to the TB epidemic.<\/p>\n\n\n\n<p>Hon Stephen Mule, a Kenyan parliamentarian, has been in the lead in urging his colleagues to sign in the declaration in demonstration of their support to the global agenda of eliminating TB. [IDN-InDepthNews \u2013 20 October 2015]<\/p>\n\n\n\n<p>Photos top down: 1) Keiko Sano, JICA\u2019s Chief Representative in Kenya | Credit: JICA, Kenya. 2) Catherine Nduta, a Multi Drug Resistant TB survivor speaks during the recent October meeting organized by StopTB Partnership Kenya.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>NAIROBI (IDN) &#8211; Catherine Nduta, 26, was diagnosed with Multi Drug Resistant Tuberculosis (MDR-TB) in 2012, when she was a third year student at one of Kenya\u2019s universities, where she was undertaking a civil engineering course. \u201cI was almost 6-month pregnant hence couldn\u2019t start MDR-TB treatment. I was to either terminate the pregnancy for me [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3709,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[35,30,6,16,32],"tags":[],"class_list":{"0":"post-3708","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-africa","8":"category-development-aid","9":"category-goal3","10":"category-news","11":"category-regions"},"_links":{"self":[{"href":"https:\/\/inpsjapan.com\/en\/wp-json\/wp\/v2\/posts\/3708","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inpsjapan.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inpsjapan.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inpsjapan.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inpsjapan.com\/en\/wp-json\/wp\/v2\/comments?post=3708"}],"version-history":[{"count":2,"href":"https:\/\/inpsjapan.com\/en\/wp-json\/wp\/v2\/posts\/3708\/revisions"}],"predecessor-version":[{"id":3711,"href":"https:\/\/inpsjapan.com\/en\/wp-json\/wp\/v2\/posts\/3708\/revisions\/3711"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/inpsjapan.com\/en\/wp-json\/wp\/v2\/media\/3709"}],"wp:attachment":[{"href":"https:\/\/inpsjapan.com\/en\/wp-json\/wp\/v2\/media?parent=3708"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inpsjapan.com\/en\/wp-json\/wp\/v2\/categories?post=3708"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inpsjapan.com\/en\/wp-json\/wp\/v2\/tags?post=3708"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}